[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:indolent-b-cell-non-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":29,"states":30},"Indolent B-Cell Non-Hodgkin Lymphoma",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06386315","Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma",[11],"Phase 2","RECRUITING","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:28.854645Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT03571568","A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL",[19],"Phase 1\u002FPhase 2","2026-08-26T02:18:38.077159Z","2026-05-05T02:43:29.721924Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT05755087","Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma",[26],"Phase 1","2026-08-26T02:17:39.857430Z","2026-05-05T02:43:27.642521Z",[],[]]